Clinical Trials Browser

Phase 1 × ciforadenant × Plasma cell × Clear all

NCT04280328 2022-03-11

Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Completed

Multiple Myeloma